Full Press Release Details
CureVac Welcomes Myriam
Mendila as New Chief Development Officer
BOSTON, USA - February 1, 2023 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class
of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Myriam Mendila has taken up
her role as CureVac's Chief Development Officer, as previously announced.
extensive expertise in product development in the global pharmaceutical industry, particularly the past several years in oncology, will
be a significant asset to CureVac as we continue to advance our mRNA product pipeline. On behalf of the entire team, I would like to offer
Myriam a very warm welcome as a new member of CureVac's management," said Franz-Werner Haas, Chief Executive Offer at CureVac.
"I would also like to extend my wholehearted thanks to Ulrike Gnad-Vogt for stepping in as Interim Chief Development Officer during
the past eight months."
excited to join CureVac at this important inflection point of the company," said Dr. Mendila. "The latest data update from
the COVID-19 and flu programs demonstrates the potential of CureVac's broad technology platform to help fighting the most pressing
health challenges and supports its competitive position as a key player in the mRNA field. I'm looking forward to working with the
CureVac team to build on these data, not only in infectious diseases but across CureVac's therapeutic areas."
Myriam Mendila, MD, has
more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as
global product strategy, including commercial strategy at Roche, Genentech and Novartis. Over the last 5 years, she has held the position
of Chief Medical Officer Oncology and Global Head of Oncology Medical Affairs at Novartis, being responsible for the Medical Affairs strategy
and related activities across the overall oncology portfolio at Novartis. Myriam earned her medical degree and subsequently doctoral degree
from the Medical University of Hannover, Germany.
CureVac (Nasdaq: CVAC) is a
global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing,
optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology
is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range
of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious
diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation
COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical
pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac
N.V. has its headquarters in T bingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands,
Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.
CureVac Investor Relations
Dr. Sarah Fakih, Vice President Corporate
Communications and Investor Relations
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
CureVac Media Contact
Bettina J dicke-Braas, Manager Communications
CureVac, T bingen, Germany
T: +49 7071 9883-1087
Forward-Looking Statements CureVac
This press release contains statements that constitute
"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or
its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future
results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's
vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some
cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe,"
"estimate," "plan," "seek," "project," or "expect," "may," "will,"
"would," "could," "potential," "intend," or "should," the negative of these
terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information
currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance,
and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial
markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense
and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability
to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's
business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake,
and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as required by law.
For further information, please reference the
company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at www.sec.gov.